1. Clinical Overview
A comprehensive topical quadruple-action cream indicated for the treatment of mixed dermatological infections, particularly those involving dermatophytes, bacteria, and anaerobic organisms, with a potent corticosteroid component for rapid anti-inflammatory and anti-pruritic relief. It is a rational fixed-dose combination (FDC) widely used in the Indian market for conditions like infected eczema, infected tinea, and other inflammatory dermatoses with secondary infection.
| Onset | Duration | Bioavailability |
|---|---|---|
| Clobetasol's anti-inflammatory and antipruritic effects begin within 1-3 hours. Antimicrobial effects (Ofloxacin, Ornidazole, Terbinafine) typically show symptomatic improvement within 24-48 hours. | Topical application provides localized effect for approximately 8-12 hours per application. Systemic absorption of components is minimal with appropriate use. | Topical bioavailability is variable. Systemic absorption is minimal (<5% for each component) when applied to intact skin, but increases with application to inflamed skin, broken skin, occlusive dressings, or large surface areas. |
2. Mechanism of Action
This combination exerts a multifaceted action: 1) Terbinafine inhibits fungal squalene epoxidase, leading to ergosterol deficiency and fungal cell death. 2) Clobetasol is a potent glucocorticoid receptor agonist inducing anti-inflammatory, immunosuppressive, and antipruritic effects via complex genomic pathways. 3) Ofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, causing bactericidal activity. 4) Ornidazole undergoes intracellular reduction of its nitro group, generating toxic intermediates that damage DNA and other macromolecules in anaerobic bacteria and protozoa.
3. Indications & Uses
- Infected eczema/dermatitis
- Infected tinea corporis/cruris/pedis (with bacterial superinfection)
- Inflamed seborrheic dermatitis with secondary infection
- Infected psoriasis plaques (under strict supervision)
- Mixed bacterial/fungal skin infections
4. Dosage & Administration
Adult Dosage: Apply a thin film to the affected area twice daily, gently rubbing in. Duration: Usually for 1-2 weeks. Maximum duration should not exceed 4 weeks. Review by physician after 2 weeks is mandatory.
Administration: 1. Wash and dry the affected area thoroughly. 2. Take a small amount of cream on a clean fingertip. 3. Apply a thin layer and rub gently until absorbed. 4. Wash hands after application unless hands are the treatment site. 5. Do not cover with occlusive dressings unless specifically advised by a doctor. 6. Avoid contact with eyes, nose, mouth, and mucous membranes.
5. Side Effects
Common side effects may include:
- Local burning or stinging sensation (especially on broken skin)
- Itching (pruritus) at application site
- Dryness of skin
- Erythema (redness)
- Skin irritation
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Systemic Corticosteroids (e.g., Prednisolone) | Additive risk of adrenal suppression and Cushingoid features. | Major |
| Other Topical Corticosteroids | Increased risk of local and systemic steroid adverse effects. | Major |
| Systemic Fluoroquinolones (e.g., Ciprofloxacin) | Theoretical additive risk of tendon disorders; clinical significance with topical use is low. | Moderate |
| Warfarin and other Coumarin Anticoagulants | Ornidazole and ofloxacin may potentiate anticoagulant effect by various mechanisms (inhibition of metabolism, alteration of gut flora). Monitor INR if large areas are treated. | Moderate |
| CYP450 Inducers (e.g., Rifampicin, Phenytoin, Carbamazepine) | May reduce systemic levels of terbinafine and ornidazole if absorbed. | Minor |
| CYP450 Inhibitors (e.g., Cimetidine, Ketoconazole) | May increase systemic levels of terbinafine and ornidazole if absorbed. | Minor |
| Alcohol | Disulfiram-like reaction (flushing, tachycardia, nausea) is possible with systemic absorption of ornidazole. Patients should be cautioned. | Moderate |
7. Patient Counselling
- DO use exactly as prescribed by your doctor.
- DO wash and dry the area before application.
- DO use a thin layer; more cream does not mean faster healing.
- DO wash your hands after application (unless treating hands).
- DON'T apply on the face, underarms, or groin unless specifically told to do so.
- DON'T cover the area with tight bandages or plastic wraps unless advised.
- DON'T use for longer than the prescribed duration (usually 1-2 weeks).
- DON'T share this medicine with others.
- DON'T use it for any other skin condition.
8. Toxicology & Storage
Overdose: Topical overdose manifests as intensified local side effects: severe skin atrophy, striae, telangiectasia, HPA axis suppression symptoms (fatigue, weakness, nausea, hypotension, hyperglycemia). Accidental ingestion would cause symptoms specific to each drug: GI upset, CNS effects (dizziness, seizures from ornidazole), hepatotoxicity (terbinafine).
Storage: Store below 25°C, in a cool and dry place. Protect from light and moisture. Do not freeze. Keep the tube tightly closed. Keep out of reach and sight of children. Do not use after the expiry date printed on the pack.